Published in Lancet on August 24, 2009
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One (2010) 3.48
A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS One (2010) 3.38
HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev (2011) 3.28
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med (2010) 2.86
Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis (2010) 2.85
Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol (2010) 2.53
High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med (2010) 2.23
Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS (2011) 2.21
Verbal autopsy interpretation: a comparative analysis of the InterVA model versus physician review in determining causes of death in the Nairobi DSS. Popul Health Metr (2010) 2.04
Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis (2010) 1.92
Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis (2011) 1.76
Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med (2013) 1.73
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa. J Infect Dis (2010) 1.69
Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis (2012) 1.56
Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation. Curr Pharmacogenomics Person Med (2011) 1.49
Co-infection with Mycobacterium tuberculosis impairs HIV-Specific CD8+ and CD4+ T cell functionality. PLoS One (2015) 1.47
Pulmonary resection for extensively drug resistant tuberculosis in Kwazulu-Natal, South Africa. Ann Thorac Surg (2012) 1.40
An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One (2013) 1.36
Exposing misclassified HIV/AIDS deaths in South Africa. Bull World Health Organ (2011) 1.31
Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr (2011) 1.31
Evaluation of the Cobas TaqMan MTB test for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol (2010) 1.30
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials (2011) 1.15
Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. Glob Public Health (2014) 1.12
Risk factors for hospitalized seasonal influenza in rural western Kenya. PLoS One (2011) 1.10
New antipoverty drugs, vaccines, and diagnostics: a research agenda for the US President's Global Health Initiative (GHI). PLoS Negl Trop Dis (2011) 1.08
Indoor social networks in a South African township: potential contribution of location to tuberculosis transmission. PLoS One (2012) 1.08
Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis (2010) 1.07
Substance use, gender inequity, violence and sexual risk among couples in Cape Town. Cult Health Sex (2013) 1.07
Economic support to improve tuberculosis treatment outcomes in South Africa: a pragmatic cluster-randomized controlled trial. Trials (2013) 1.06
Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev (2014) 1.03
The unfolding counter-transition in rural South Africa: mortality and cause of death, 1994-2009. PLoS One (2014) 1.02
Supporting the massive scale-up of antiretroviral therapy: the evolution of PEPFAR-supported treatment facilities in South Africa, 2005-2009. BMC Public Health (2012) 1.00
Social constraints to TB/HIV healthcare: accounts from coinfected patients in South Africa. AIDS Care (2012) 0.98
Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region. PLoS One (2013) 0.98
Engagement of non-government organisations and community care workers in collaborative TB/HIV activities including prevention of mother to child transmission in South Africa: opportunities and challenges. BMC Health Serv Res (2012) 0.97
HIV-1 and the immune response to TB. Future Virol (2013) 0.97
Migration and the epidemiological transition: insights from the Agincourt sub-district of northeast South Africa. Glob Health Action (2014) 0.96
Control of (multi)drug resistance and tuberculosis incidence over 23 years in the context of a well-supported tuberculosis programme in rural Malawi. PLoS One (2013) 0.96
Moving towards universal coverage in South Africa? Lessons from a voluntary government insurance scheme. Glob Health Action (2013) 0.96
Tuberculosis surveillance using a hidden markov model. Iran J Public Health (2012) 0.95
Psychological and physical co-morbidity among urban South African women. PLoS One (2013) 0.95
Characteristics, availability and uses of vital registration and other mortality data sources in post-democracy South Africa. Glob Health Action (2012) 0.94
Ethnic differences in alcohol and drug use and related sexual risks for HIV among vulnerable women in Cape Town, South Africa: implications for interventions. BMC Public Health (2013) 0.94
Evidence for localised HIV related micro-epidemics associated with the decentralised provision of antiretroviral treatment in rural South Africa: a spatio-temporal analysis of changing mortality patterns (2007-2010). J Glob Health (2014) 0.93
Validating the InterVA model to estimate the burden of mortality from verbal autopsy data: a population-based cross-sectional study. PLoS One (2013) 0.93
Evaluation of tuberculosis diagnostics: establishing an evidence base around the public health impact. J Infect Dis (2011) 0.92
Prevalence and correlates of depression among HIV-infected and -affected older people in rural South Africa. J Affect Disord (2013) 0.92
InterVA versus Spectrum: how comparable are they in estimating AIDS mortality patterns in Nairobi's informal settlements? Glob Health Action (2013) 0.91
Risk of Death among HIV Co-Infected Multidrug Resistant Tuberculosis Patients, Compared To Mortality in the General Population of South Africa. J AIDS Clin Res (2013) 0.91
Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS One (2012) 0.91
Timing, rates, and causes of death in a large South African tuberculosis programme. BMC Infect Dis (2014) 0.91
The hidden harm of home-based care: pulmonary tuberculosis symptoms among children providing home medical care to HIV/AIDS-affected adults in South Africa. AIDS Care (2013) 0.89
Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa. BMC Infect Dis (2014) 0.88
Atypical squamous cells, cannot exclude high grade squamous intraepithelial (ASC-H) in HIV-positive women. Cytojournal (2010) 0.88
Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa. Antivir Ther (2012) 0.88
Integrating patients' perspectives into integrated tuberculosis-human immunodeficiency virus health care. Int J Tuberc Lung Dis (2013) 0.88
Why increasing availability of ART is not enough: a rapid, community-based study on how HIV-related stigma impacts engagement to care in rural South Africa. BMC Public Health (2016) 0.87
HIV infection in high school students in rural South Africa: role of transmissions among students. AIDS Res Hum Retroviruses (2014) 0.86
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. Antivir Ther (2012) 0.86
Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. Lancet HIV (2016) 0.86
The relationship between (stigmatizing) views and lay public preferences regarding tuberculosis treatment in the Eastern Cape, South Africa. Int J Equity Health (2011) 0.85
Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting. AIDS Behav (2015) 0.85
Strengthening HIV surveillance in the antiretroviral therapy era: rationale and design of a longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, KwaZulu-Natal, South Africa. BMC Public Health (2015) 0.85
Evaluation of tuberculosis infection control measures implemented at primary health care facilities in Kwazulu-Natal province of South Africa. BMC Infect Dis (2015) 0.84
Experience in international clinical research: the HIV Prevention Trials Network. Clin Investig (Lond) (2011) 0.84
Concurrent use of traditional medicine and ART: Perspectives of patients, providers and traditional healers in Durban, South Africa. Glob Public Health (2014) 0.84
The impact of HIV, an antiretroviral programme and tuberculosis on mortality in South African platinum miners, 1992-2010. PLoS One (2012) 0.84
Health systems in Africa: learning from South Africa. Lancet (2009) 0.84
Mortality associated with tuberculosis/HIV co-infection among patients on TB treatment in the Limpopo province, South Africa. Afr Health Sci (2014) 0.83
Antiretroviral treatment as prevention: impact of the 'test and treat' strategy on the tuberculosis epidemic. Curr HIV Res (2011) 0.83
Depression, disability and functional status among community-dwelling older adults in South Africa: evidence from the first South African National Income Dynamics Study. Int J Geriatr Psychiatry (2013) 0.83
Informing comprehensive HIV prevention: a situational analysis of the HIV prevention and care context, North West Province South Africa. PLoS One (2014) 0.83
A strategy for developing future academic leaders for South Africa in a resource-constrained environment. Acad Med (2014) 0.83
Ubiquitous burden: the contribution of migration to AIDS and Tuberculosis mortality in rural South Africa. Etude Popul Afr (2014) 0.83
Determinants of the risk of dying of HIV/AIDS in a rural South African community over the period of the decentralised roll-out of antiretroviral therapy: a longitudinal study. Glob Health Action (2014) 0.83
Health-related quality of life dynamics of HIV-positive South African women up to ART initiation: evidence from the CAPRISA 002 acute infection cohort study. AIDS Behav (2014) 0.82
When HIV is ordinary and diabetes new: remaking suffering in a South African township. Glob Public Health (2015) 0.82
Adult HIV care resources, management practices and patient characteristics in the Phase 1 IeDEA Central Africa cohort. J Int AIDS Soc (2012) 0.82
The experiences of people living with HIV/AIDS and of their direct informal caregivers in a resource-poor setting. J Int AIDS Soc (2010) 0.81
Understanding HIV Risk Behavior from a Sociocultural Perspective. J AIDS Clin Res (2012) 0.81
Beyond Comorbidity: A Critical Perspective of Syndemic Depression and Diabetes in Cross-cultural Contexts. Med Anthropol Q (2015) 0.81
The relevance of social contexts and social action in reducing substance use and victimization among women participating in an HIV prevention intervention in Cape Town, South Africa. Subst Abuse Rehabil (2013) 0.81
Perceptions of Community Members and Healthcare Workers on Male Involvement in Prevention of Mother-To-Child Transmission Services in Khayelitsha, Cape Town, South Africa. PLoS One (2015) 0.81
The Nkateko health service trial to improve hypertension management in rural South Africa: study protocol for a randomised controlled trial. Trials (2014) 0.80
Economic support to improve tuberculosis treatment outcomes in South Africa: a qualitative process evaluation of a cluster randomized controlled trial. Trials (2014) 0.80
The contrasting cultures of HIV and tuberculosis care. AIDS (2015) 0.79
HIV/AIDS-related stigma in South African alcohol-serving venues and its potential impact on HIV disclosure, testing and treatment-seeking behaviours. Glob Public Health (2015) 0.79
Viewpoint discrimination and contestation of ideas on its merits, leadership and organizational ethics: expanding the African bioethics agenda. BMC Med Ethics (2013) 0.79
Fatal nosocomial MDR TB identified through routine genetic analysis and whole-genome sequencing. Emerg Infect Dis (2015) 0.79
Understanding HIV-infected patients' experiences with PEPFAR-associated transitions at a Centre of Excellence in KwaZulu Natal, South Africa: a qualitative study. AIDS Care (2015) 0.79
HIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up. Medicine (Baltimore) (2015) 0.79
Adapting an evidence-based HIV behavioral intervention for South African couples. Subst Abuse Treat Prev Policy (2015) 0.78
"It's a different condom, let's see how it works": young men's reactions to and experiences of female condom use during an intervention trial in South Africa. J Sex Res (2013) 0.78
Adverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa. Medicine (Baltimore) (2016) 0.78
Changing use of traditional healthcare amongst those dying of HIV related disease and TB in rural South Africa from 2003 - 2011: a retrospective cohort study. BMC Complement Altern Med (2014) 0.78
Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale J Biol Med (2011) 0.78
Diabetes care among urban women in Soweto, South Africa: a qualitative study. BMC Public Health (2015) 0.78
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med (2005) 42.71
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (2006) 21.60
Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med (2007) 19.78
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med (2008) 7.47
Integrating HIV prevention and treatment: from slogans to impact. PLoS Med (2005) 6.73
The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med (2006) 6.53
Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68
The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis (2003) 5.09
Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa. AIDS (2003) 4.87
Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ (2008) 4.54
Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis (2007) 3.74
Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis (2008) 3.33
Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev (2004) 2.95
Seroprevalence of HIV infection in rural South Africa. AIDS (1992) 2.22
Human immunodeficiency virus and migrant labor in South Africa. Int J Health Serv (1991) 2.15
Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS (2003) 2.11
Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health (2005) 2.09
Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A (2008) 2.03
Eliminating human tuberculosis in the twenty-first century. J R Soc Interface (2008) 2.00
Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop Med Int Health (2004) 1.89
Implementation issues in tuberculosis/HIV program collaboration and integration: 3 case studies. J Infect Dis (2007) 1.70
Promoting retention in care: an effective model in an antiretroviral treatment service in South Africa. Clin Infect Dis (2007) 1.55
Modeling the joint epidemics of TB and HIV in a South African township. J Math Biol (2008) 1.31
Characterization of full-length HIV type 1 subtype C sequences from South Africa. AIDS Res Hum Retroviruses (2001) 1.23
Regional prevalence of hepatitis B, delta, and human immunodeficiency virus infection in southern Africa: a large population survey. Am J Epidemiol (1989) 1.08
Socio-medical indicators of health in South Africa. Int J Health Serv (1986) 1.05
AIDS and South Africa--towards a comprehensive strategy. Part I. The world-wide experience. S Afr Med J (1988) 1.01
Changes in HIV seroprevalence in a rural black community in KwaZulu. S Afr Med J (1992) 0.93
Tuberculosis and the development of industrial health policies on the Witwatersrand, 1902-1932. J South Afr Stud (1987) 0.92
Antiretroviral therapy: challenges and options in South Africa. Lancet (2003) 0.91
Workplace discrimination. Helping the spread of HIV. S Afr Labour Bull (1995) 0.91
Demography and economics of HIV/AIDS. Br Med Bull (2001) 0.90
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91
Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet (2006) 5.98
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS (2008) 5.26
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
The HIV-associated tuberculosis epidemic--when will we act? Lancet (2010) 3.82
Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis (2009) 3.77
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One (2010) 3.48
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet (2009) 3.35
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med (2004) 3.26
Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS (2007) 3.19
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS (2005) 3.16
Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc (2012) 3.00
Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis (2010) 2.86
Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.72
Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr (2007) 2.67
Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet (2006) 2.65
Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis (2002) 2.60
Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS (2010) 2.60
Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One (2012) 2.53
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis (2010) 2.38
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis (2008) 2.32
Extensively drug resistant tuberculosis. BMJ (2006) 2.29
How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS (2005) 2.28
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis (2009) 2.25
Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health (2010) 2.19
Antiretroviral prophylaxis: a defining moment in HIV control. Lancet (2011) 2.17
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr (2011) 2.16
Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. Psychol Health Med (2007) 2.08
HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med (2009) 2.07
Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis (2008) 2.05
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr (2010) 2.05
Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull World Health Organ (2010) 2.03
Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world? Clin Infect Dis (2005) 1.98
"That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health (2008) 1.96
Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS (2010) 1.94
Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis (2006) 1.91
Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa. PLoS Med (2006) 1.90
A model designed to enhance informed consent: experiences from the HIV prevention trials network. Am J Public Health (2005) 1.89
AIDS research must link to local policy. Nature (2010) 1.81
Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis (2012) 1.72
Tuberculosis control has failed in South Africa--time to reappraise strategy. S Afr Med J (2011) 1.70
Optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis: there may be more than one right answer. J Acquir Immune Defic Syndr (2007) 1.68
Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status. PLoS One (2011) 1.63
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis (2013) 1.62
Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol (2003) 1.61
How can earlier entry of patients into antiretroviral programs in low-income countries be promoted? Clin Infect Dis (2006) 1.60
Location of Xpert® MTB/RIF in centralised laboratories in South Africa undermines potential impact. Int J Tuberc Lung Dis (2012) 1.58
Promoting retention in care: an effective model in an antiretroviral treatment service in South Africa. Clin Infect Dis (2007) 1.55
Patients' readiness to start highly active antiretroviral treatment for HIV. BMJ (2005) 1.54
Should the CD4 threshold for starting ART be raised? Lancet (2009) 1.54
Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. PLoS One (2012) 1.53
Evaluation of a workplace HIV treatment programme in South Africa. AIDS (2007) 1.52
Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis (2012) 1.50
Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS (2010) 1.50
Tuberculosis transmission to young children in a South African community: modeling household and community infection risks. Clin Infect Dis (2010) 1.49
Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. AIDS (2009) 1.49
Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. BMC Infect Dis (2012) 1.46
Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection. J Infect Dis (2008) 1.42
A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr (2004) 1.42
Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries. Clin Infect Dis (2005) 1.41
Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis (2008) 1.41
Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis. J Acquir Immune Defic Syndr (2011) 1.41
Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One (2013) 1.41
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS (2012) 1.40
Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. J Acquir Immune Defic Syndr (2012) 1.39
Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis (2003) 1.36
An incentivized HIV counseling and testing program targeting hard-to-reach unemployed men in Cape Town, South Africa. J Acquir Immune Defic Syndr (2012) 1.35
Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One (2013) 1.35
High prevalence of self-reported undiagnosed HIV despite high coverage of HIV testing: a cross-sectional population based sero-survey in South Africa. PLoS One (2011) 1.33
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS (2008) 1.32
Adjunctive tests for diagnosis of tuberculosis: serology, ELISPOT for site-specific lymphocytes, urinary lipoarabinomannan, string test, and fine needle aspiration. J Infect Dis (2011) 1.31
Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr (2011) 1.31
Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health (2010) 1.30
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One (2013) 1.29
Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study. PLoS Med (2012) 1.29
Practice brief: adolescents and HIV clinical trials: ethics, culture, and context. J Assoc Nurses AIDS Care (2007) 1.29
Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. Clin Infect Dis (2010) 1.29
Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2012) 1.26
Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. PLoS One (2013) 1.24
Tuberculosis in a South African prison - a transmission modelling analysis. S Afr Med J (2011) 1.24
Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr (2011) 1.22
HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc (2012) 1.21
Accelerated biological ageing in HIV-infected individuals in South Africa: a case-control study. AIDS (2013) 1.20
The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS (2006) 1.19
Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care (Chic) (2012) 1.19
Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model. J Acquir Immune Defic Syndr (2013) 1.18
HIV-prevention science at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS (2009) 1.18